Efficacy News and Research

RSS
Computerized cognitive testing plays a key role in therapy development for dementia, AD

Computerized cognitive testing plays a key role in therapy development for dementia, AD

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

Study: Ultrasound waves applied to specific areas of brain appear to alter patients' moods

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

Spinal Restoration: Success criteria not met for primary analysis of Phase III study of Biostat System

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Human filariasis research: an interview with Professor Mark Taylor, Liverpool School of Tropical Medicine

Creating, promoting foods containing angiogenesis is the new frontier in dietary health

Creating, promoting foods containing angiogenesis is the new frontier in dietary health

Study may allow more patients to benefit from transcatheter aortic valve replacement

Study may allow more patients to benefit from transcatheter aortic valve replacement

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Rexahn Pharmaceuticals signs license agreement with UMB for novel drug delivery platform

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Adynxx receives FDA Fast Track designation for AYX1 Injection to treat chronic pain

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Sequella licenses Pfizer's exclusive worldwide rights to develop, commercialize sutezolid

Combination therapy during cardiac arrest results in improved hospital discharge and neurological status

Combination therapy during cardiac arrest results in improved hospital discharge and neurological status

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

FDA accepts Iroko's submicron indomethacin NDA for treatment of acute pain in adults

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Furiex Pharmaceuticals enrolls patient for Phase III clinical trial of eluxadoline for treatment of diarrhea

Study shows flavonoid-based nutritional supplements can affect endocrine system

Study shows flavonoid-based nutritional supplements can affect endocrine system

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

ADC Therapeutics, BZL Biologics sign licensing deal for antibody against PSMA-positive prostate cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.